Eman Salah Albeltagy1, Shaimaa Younes Abd Elaziz2, Sarah Younes Abozaid3, Hala Mohamed El Zomor4, Sally Said Abd Elhamed5. 1. Department of Internal Medicine, Faculty of Medicine (For Girls), Al-Azhar University, Cairo, Egypt. drbeleman@yahoo.com. 2. Department of Psychiatry, Faculty of Medicine (For Girls), Al-Azhar University, Cairo, Egypt. 3. Department of Clinical Pathology, Faculty of Medicine (For Girls), Al-Azhar University, Cairo, Egypt. 4. Department of Rheumatology and Rehabilitation, Faculty of Medicine (For Girls), Al-Azhar University, Cairo, Egypt. 5. Department of Internal Medicine, Faculty of Medicine (For Girls), Al-Azhar University, Cairo, Egypt.
Abstract
OBJECTIVE: Depression is very prevalent in rheumatoid arthritis (RA) compared with the general population and may be associated with poor clinical outcomes. Identifying factors associated with depression could improve outcomes for this at risk group. However, few studies have comprehensively examined the association of contextual and disease-related factors as well as pro inflammatory cytokines interleukin 6 (IL-6) and interleukin 17 (IL-17) with depression in RA. Therefore, we aimed to identify the factors significantly associated with depression and severe depression in RA, thus providing a reference for applying clinical care interventions for patients with RA. METHODS: An observational cross-sectional study was conducted on 120 RA patients. Potential determinants included contextual and disease-related factors and laboratory variables. Enzyme-linked immunosorbent assay was used to measure serum IL-6 and IL-17 levels. Depression was assessed using the Arabic version of the Beck Depression Inventory-II questionnaire. RESULTS: A total of 120 patients were included, and up to 67.5% had some degree of depression with 60% having moderate to severe depression. The severity of disease activity of RA (DAS28-ESR (OR, 1.63; 95% CI, 0.899-3.755), HAQ scores (OR, 1.27; 95% CI, 0.702-2.933), and VAS scores for pain (OR, 2.2; 95% CI, 1.251-5.223)), besides elevated serum IL-6 (OR, 1.51; 95% CI, 0.832-3.475), IL-17 (OR, 1.28; 95% CI, 0.706-2.947), and CRP levels (OR, 1.20; 95% CI, 0.923-2.882) were significantly associated with depression and its severity in the multivariate analysis. CONCLUSION: Depression is frequent in RA and is strongly associated to elevated serum IL-6, IL-17, CRP levels, and disease activity-related factors. Key Points • RA patients are at increased risk of developing depression, particularly if their level of disease activity scores, serum IL-6, and IL-17 levels increases. • Patient characteristics associated with depression in RA include living without family, without employments, and with co-morbid hypertension, while RA disease factors are pain, functional disability, and high disease activity. • A multidisciplinary cooperative approach to RA patient care with regular assessments of these factors associated with depression should be incorporated into routine care programs to improve patients' self care capabilities and mitigate or prevent depression in these patients.
OBJECTIVE: Depression is very prevalent in rheumatoid arthritis (RA) compared with the general population and may be associated with poor clinical outcomes. Identifying factors associated with depression could improve outcomes for this at risk group. However, few studies have comprehensively examined the association of contextual and disease-related factors as well as pro inflammatory cytokines interleukin 6 (IL-6) and interleukin 17 (IL-17) with depression in RA. Therefore, we aimed to identify the factors significantly associated with depression and severe depression in RA, thus providing a reference for applying clinical care interventions for patients with RA. METHODS: An observational cross-sectional study was conducted on 120 RA patients. Potential determinants included contextual and disease-related factors and laboratory variables. Enzyme-linked immunosorbent assay was used to measure serum IL-6 and IL-17 levels. Depression was assessed using the Arabic version of the Beck Depression Inventory-II questionnaire. RESULTS: A total of 120 patients were included, and up to 67.5% had some degree of depression with 60% having moderate to severe depression. The severity of disease activity of RA (DAS28-ESR (OR, 1.63; 95% CI, 0.899-3.755), HAQ scores (OR, 1.27; 95% CI, 0.702-2.933), and VAS scores for pain (OR, 2.2; 95% CI, 1.251-5.223)), besides elevated serum IL-6 (OR, 1.51; 95% CI, 0.832-3.475), IL-17 (OR, 1.28; 95% CI, 0.706-2.947), and CRP levels (OR, 1.20; 95% CI, 0.923-2.882) were significantly associated with depression and its severity in the multivariate analysis. CONCLUSION: Depression is frequent in RA and is strongly associated to elevated serum IL-6, IL-17, CRP levels, and disease activity-related factors. Key Points • RA patients are at increased risk of developing depression, particularly if their level of disease activity scores, serum IL-6, and IL-17 levels increases. • Patient characteristics associated with depression in RA include living without family, without employments, and with co-morbid hypertension, while RA disease factors are pain, functional disability, and high disease activity. • A multidisciplinary cooperative approach to RA patient care with regular assessments of these factors associated with depression should be incorporated into routine care programs to improve patients' self care capabilities and mitigate or prevent depression in these patients.
Entities:
Keywords:
Depression; IL-17; IL-6; RA disease activity; Rheumatoid arthritis
Authors: Lena M Hassen; Rana A Albarrak; Reem A Albahlal; Dimah K Alsaqabi; Ikhlass M Hassen; Maha H Daghestani; Eman M Alqurtas; Abdulaziz T Alkhalaf; Mohammed K Bedaiwi; Mohammed A Omair; Ibrahim A Almaghlouth Journal: Qual Life Res Date: 2022-07-20 Impact factor: 3.440
Authors: Carly A Hunt; Chung Jung Mun; Michael A Owens; Sheera F Lerman; Shriya Kunatharaju; Howard A Tennen; Luis F Buenaver; Claudia M Campbell; Jennifer A Haythornthwaite; Michael T Smith; Patrick H Finan Journal: Psychosom Med Date: 2022-04-01 Impact factor: 4.312
Authors: Małgorzata Gałecka; Katarzyna Bliźniewska-Kowalska; Agata Orzechowska; Janusz Szemraj; Michael Maes; Michael Berk; Kuan-Pin Su; Piotr Gałecki Journal: J Pers Med Date: 2021-01-23
Authors: Katarzyna Bliźniewska-Kowalska; Bernadeta Szewczyk; Małgorzata Gałecka; Kuan-Pin Su; Michael Maes; Janusz Szemraj; Piotr Gałecki Journal: J Clin Med Date: 2020-12-12 Impact factor: 4.241
Authors: Hasan Najah Smesam; Hasan Abbas Qazmooz; Sinan Qayes Khayoon; Abbas F Almulla; Hussein Kadhem Al-Hakeim; Michael Maes Journal: J Pers Med Date: 2022-03-16